Permanent Impairment After Cancer Treatment

Permanent impairment after cancer treatment: the NDIS pathway nobody tells you about

A woman finishes treatment for ovarian cancer. She is told she is in remission. She also cannot feel her feet, cannot do up a button, falls regularly, and has given up driving. The neuropathy is from the platinum chemotherapy and after two years it has not improved and is not expected to.

Nobody has mentioned the NDIS to her. Her oncologist deals with cancer. Her GP associates the scheme with lifelong disability. Her own mental model is that she is a cancer survivor with side effects, not a person with a disability.

She is 61, and she has four years to apply.

This is the most consistently missed pathway in the relationship between cancer and disability, and it is missed in both directions. People with cancer-related impairment do not know the scheme might apply to them. Clinicians often assume it does not. And the scheme itself has no mechanism for finding these people, because nothing in the cancer pathway prompts anybody to ask the question.

This comes from a registered NDIS provider working across New South Wales. No part of it is medical advice and we provide no clinical care. What we can set out is how the access test actually works and what an application needs to contain, because the reason these applications fail is usually how they were built rather than whether the person qualified.

The rule that makes this possible

The NDIA’s guidance states plainly that access does not depend on how the impairment arose.

This is the sentence everything else rests on. The scheme does not have a list of approved causes. It does not ask whether your impairment came from a congenital condition, an accident, a stroke, a degenerative disease or cancer treatment. It asks whether you have impairment that is permanent or likely to be permanent, and whether it substantially reduces your functional capacity.

The same guidance makes the corollary explicit: the NDIS does not fund medication or medical care for treating a chronic condition, but disability supports may still be available where a health condition causes a disability — and the example it gives is amputation.

So the position is:

• The cancer is a health condition. Health system. Not an NDIS matter.
• The impairment the cancer or its treatment left behind is an impairment. Assessed on its own terms.

That distinction is not a technicality. It is the entire basis of the application, and getting it the wrong way round is the most common reason these applications are refused.

What the access test actually requires

To meet the disability access criteria, a person needs impairment that is permanent or likely to be permanent, and that results in substantially reduced functional capacity in at least one of six domains:

• Communication
• Social interaction
• Learning
• Mobility
• Self-care
• Self-management

Permanence means there is no known, available and appropriate treatment that would remedy the impairment. It does not mean the impairment can never change or will never be managed. Importantly, impairment can be permanent even where it fluctuates in intensity — the NDIS position is that an impairment may be episodic or fluctuate, and that needs going up and down over time does not disqualify somebody.

That last point matters for cancer-related impairment, because several of the relevant impairments vary. Lymphoedema flares. Neuropathy is worse in cold weather. Fatigue varies. The NDIA’s own wording is that it considers a person’s ability over time, taking into account their ups and downs.

Cancer is not on List A or List B — the lists of conditions where permanence is presumed or likely. That is not a bar, since most participants do not enter via the lists, but it means permanence has to be established with evidence rather than assumed.

The impairments that come out of cancer treatment

This is the catalogue. For each one, the question is the same: is it permanent, and what functional capacity does it reduce?

Chemotherapy-induced peripheral neuropathy

The most common permanent impairment from cancer treatment, and the most consistently overlooked.

Several widely used drug classes cause it — platinum agents, taxanes, vinca alkaloids, and others. It produces numbness, tingling, burning pain, loss of proprioception and loss of fine motor control, usually in a glove-and-stocking distribution. In many people it improves after treatment. In a substantial minority it does not.

Functional consequences: falls, loss of balance, inability to feel hot surfaces or injuries to the feet, loss of fine motor function affecting buttons, zips, cutlery, keys, phones and writing, inability to drive, pain affecting sleep.

Domains engaged: mobility, self-care, and sometimes self-management.

The evidence that matters: a neurologist’s or oncologist’s statement that the neuropathy is permanent, that time for recovery has elapsed, and that no further treatment is expected to remedy it. Nerve conduction studies where available. An occupational therapy functional assessment covering hand function and an assessment of falls risk and balance.

The timing problem: neuropathy improves for up to two years in some people, which means an application at six months will often be met with “it may still recover”. That is a legitimate clinical position. It is also why the application usually works better after a documented plateau — and why, if the person is near 65, waiting is not an option.

Amputation

The NDIA uses this as its own worked example. A limb amputated for a bone or soft tissue sarcoma is permanent in the same way an amputation from trauma is permanent.

Note the List A position: amputation or congenital absence of two limbs is on List A, meaning permanence and substantially reduced functional capacity are taken as given. A single amputation is not on List A and is assessed on functional capacity, which it very often meets.

The evidence: the surgical record, and a rehabilitation physician’s or surgeon’s statement. Prosthetic assessment where relevant. An OT functional assessment.

Lymphoedema

Chronic swelling caused by damage to or removal of lymph nodes, most commonly after breast, gynaecological, prostate or melanoma surgery, or after radiotherapy to those areas.

Lymphoedema is chronic, progressive if unmanaged, and requires lifelong management — compression garments, manual lymphatic drainage, skin care, and vigilance about cellulitis, which can be severe.

Functional consequences: reduced limb function and range of movement, pain and heaviness, difficulty with dressing and personal care, inability to do tasks requiring the affected limb, repeated infections, and the practical burden of daily compression management.

Domains engaged: mobility, self-care.

The evidence: diagnosis and staging from the treating specialist or a lymphoedema therapist, a statement on permanence, documented management requirements, and an OT or physiotherapy functional assessment. Garment prescription and replacement schedules are useful, because ongoing assistive technology need is part of the picture.

Permanent stoma

A colostomy, ileostomy or urostomy formed as part of cancer surgery, where it is permanent rather than temporary.

Functional consequences: daily appliance management, which for somebody with limited hand function, cognitive impairment or vision loss may require assistance; dietary management; skin care; and the social and participation consequences.

Domains engaged: self-care, self-management, social interaction.

The evidence: the surgical record confirming the stoma is permanent, not reversible. A stomal therapy nurse’s assessment of what support the person needs. Note that stoma appliances themselves are generally supplied through the Stoma Appliance Scheme rather than the NDIS, so the application should be about the assistance the person needs, not about the products.

Laryngectomy and head and neck treatment effects

Total laryngectomy means a permanent tracheostoma and the loss of normal voice. Head and neck cancer treatment more broadly can leave permanent dysphagia, xerostomia, trismus, tissue fibrosis and dental consequences.

Functional consequences: communication impairment, which may be severe; permanent airway care; eating and swallowing impairment, potentially including long-term tube feeding; and the practical consequences of not being able to speak on a telephone or be understood by strangers.

Domains engaged: communication most clearly, plus self-care and social interaction.

The evidence: speech pathology assessment, which is the central document here. Surgical records. ENT statement on permanence. Communication aid assessment where relevant.

Permanent hearing loss

Platinum-based chemotherapy — cisplatin in particular — can cause permanent sensorineural hearing loss, as can radiotherapy to the head. In children treated for cancer this is a well-recognised late effect.

Note the List A position: bilateral sensorineural hearing loss greater than 90 decibels in the better ear is on List A. Below that threshold, hearing loss is assessed on functional capacity.

The evidence: audiology reports, with the specific thresholds. An ENT or audiologist statement on permanence.

Brain tumour effects

The clearest and most common cancer–NDIS intersection, covering cognitive impairment, physical impairment, communication impairment, visual field loss, fatigue, seizures and behavioural change — arising from the tumour itself, from surgery, from radiotherapy, or from all three.

This has its own guide in this library, because the evidence requirements and the history of how these applications have been handled deserve separate treatment.

Spinal cord damage

A tumour compressing the spinal cord, or surgery to remove one, can cause permanent paraplegia or tetraplegia.

Note the List A position: spinal cord or brain injury causing paraplegia, quadriplegia or tetraplegia is on List A, as is hemiplegia with severe or total loss of strength and movement. This is one of the cleanest access pathways in cancer-related impairment and it is sometimes not recognised as such because the cause was a tumour rather than trauma.

Pelvic radiotherapy effects

Radiotherapy to the pelvis — for prostate, bowel, cervical, uterine or bladder cancer — can cause permanent bowel and bladder dysfunction, including radiation proctitis and radiation cystitis, along with sexual dysfunction and, in some cases, pelvic insufficiency fractures.

Functional consequences: urgency and incontinence that restrict leaving the house, pain, and the practical management burden.

Domains engaged: self-care, social interaction.

The evidence: treating specialist statements, continence assessment, and documentation of how it limits participation. This is a category where the functional impact is often far larger than the clinical description suggests, and the application needs to make that visible.

Cognitive impairment

Beyond brain tumours, cognitive impairment can follow treatment — from cranial radiotherapy, from some chemotherapy regimens, and from the combination.

The evidence: neuropsychological assessment is the document that carries weight here. Self-report and family report of memory and concentration problems, without formal assessment, rarely establishes substantially reduced functional capacity to the scheme’s satisfaction.

Cardiac and pulmonary late effects

Anthracycline chemotherapy can cause permanent cardiac damage, and radiotherapy to the chest can affect both heart and lungs. Where this produces permanent functional limitation — exercise intolerance severe enough to limit mobility and self-care — it is an impairment, though the NDIS will treat the underlying cardiac or respiratory condition as a health matter and look only at functional consequences.

Late effects of childhood cancer treatment

The group most likely to qualify and least likely to apply.

Survivors of childhood cancer can carry impairment that emerges years or decades later: cognitive impairment from cranial radiotherapy, hearing loss from platinum agents, endocrine and growth effects, cardiac damage, musculoskeletal effects, fertility consequences, and secondary cancers.

The problem is framing. A 24-year-old who had leukaemia at six does not think of themselves as a person with a disability, and nobody in the follow-up clinic raises the NDIS. If the cognitive, hearing or physical impairment is permanent and substantially reduces functional capacity, the cause being treatment two decades ago is irrelevant to the access test.

Bone complications

Avascular necrosis from high-dose corticosteroids, and osteonecrosis of the jaw associated with some bone-targeted medications, can both cause permanent impairment with significant functional consequences.

When to apply, and the one deadline that overrides everything

There is a genuine tension here and it is worth naming rather than glossing.

The argument for waiting: permanence is the hardest part of a cancer-related application. Many of these impairments improve for a period after treatment. An application made during or immediately after treatment invites the response that recovery is still expected, which is often clinically correct. An application made after a documented plateau, with a specialist saying the impairment is now permanent, is a much stronger application.

The argument that overrides it: you cannot join the NDIS after you turn 65. The age test applies at the date of application.

So the rule is simple. If the person is comfortably under 65, build the evidence properly and apply when permanence can be evidenced. If the person is approaching 65, apply before the birthday regardless of how incomplete the evidence is. Lodged at 64 and decided at 65, it still counts as made at 64. Lodged a month after the birthday, it is not an application at all — it cannot be made, no matter how clearly the person would otherwise qualify.

For people already over 65, the pathway is Support at Home through My Aged Care on 1800 200 422. It replaced Home Care Packages on 1 November 2025, the highest classification is capped at roughly $108,000 a year, and it is means tested. That is a different and generally less generous system than an NDIS plan built on assessed need, which is precisely why the birthday matters so much.

This is not a hypothetical concern. Cancer incidence rises steeply with age, and most of the impairments catalogued above arise disproportionately in people over 55. A large share of people who acquire NDIS-type impairment through cancer acquire it close to or past the age cut-off.

How to build the application

1. Name the impairment, not the cancer. The access request should be about the neuropathy, the amputation, the lymphoedema, the cognitive impairment. Cancer appears as the cause, in one line. An application that reads as “this person has had cancer and needs support” invites a refusal on the basis that cancer is a health condition.

2. Get a specialist statement on permanence. Not a GP letter alone. The specialist who treated the impairment — oncologist, neurologist, surgeon, rehabilitation physician, ENT — writing that the impairment is permanent, that available treatment has been tried, and that no further recovery is expected. The phrase the NDIA is looking for is that there is no known, available and appropriate treatment that would remedy the impairment.

3. Get a functional capacity assessment. Usually occupational therapy. This is the document that translates impairment into the language the scheme assesses: what the person can and cannot do in communication, social interaction, learning, mobility, self-care and self-management. A strong OT report does more work than any other single document.

4. Add the discipline-specific assessment. Speech pathology for communication or swallowing. Neuropsychology for cognition. Audiology for hearing. Physiotherapy or lymphoedema therapy for limb function. Continence assessment where relevant.

5. Document the daily reality. How long tasks take. What has been given up. What assistance is already being provided and by whom. What happens on a bad day. A one-page account written by the person or a family member, specific and dated, adds something the clinical documents do not.

6. Address fluctuation head-on if it applies. Where the impairment varies, say so and quantify it — how many days a month, what the range looks like, what the worst days require. Do not hide variability, because a report describing only good days undersells the need and a report describing only bad days invites questions about consistency. The NDIA’s own position is that it considers ability over time, including ups and downs.

7. If refused, review. Internal review within three months of the decision, which the NDIA must decide within 90 days. Then the Administrative Review Tribunal, which replaced the Administrative Appeals Tribunal in October 2024, with no application fee and free advocacy available through the NDIS Appeals programme. First-attempt refusals in this area are common and are frequently overturned when the application is rebuilt around the impairment.

Why this group is invisible

Three reasons, and they compound.

Self-identification. A person who has survived cancer thinks of themselves as a cancer survivor, not a person with a disability. Those are both true, and only one of them opens a funding pathway.

Clinical framing. Oncology follow-up is oriented to recurrence surveillance. The clinic asks whether the cancer is back. It does not usually ask whether the person can manage at home, and it rarely mentions the NDIS.

Nobody owns the handover. Cancer Council Australia’s policy priorities include clarifying roles between health and disability supports, and note that eligibility for additional support is hard to determine without a clear prognosis. There is no point in the cancer pathway at which somebody is responsible for asking whether permanent impairment has been left behind and what should happen about it.

Which means the question gets asked when somebody happens to raise it. If you are reading this and it describes someone you know, you may be the only person who is going to.